Sugi Predict

Sugi Predict / Compounds / SCHEMBL4836080

SCHEMBL4836080

SCHEMBL4836080

C1CN(CCC2CC2)CCN1

nearest known ligand 0.46

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ RAD52 P43351 1/20 0.46
▸ POLB P06746 1/20 0.45
▸ SMN1; SMN2 Q16637 1/20 0.45
▸ GNAO1 P09471 4/20 0.44
▸ CXCR4 P61073 3/20 0.43
▸ HSD17B10 Q99714 1/20 0.39
▸ GNAI3 P08754 3/20 0.39
▸ GNAI1 P63096 3/20 0.39
▸ SIGMAR1 Q99720 3/20 0.37
▸ CHRM5 P08912 2/20 0.36
▸ CHRM3 P20309 2/20 0.36
▸ CHRM2 P08172 1/20 0.36
▸ CHRM4 P08173 1/20 0.36
▸ CHRM1 P11229 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6921606 1.00 RAD52 (0.46) RAD52POLBSMN1; SMN2GNAO1CXCR4
SCHEMBL12843901 0.93 GNAO1 (0.51) RAD52POLBSMN1; SMN2GNAO1CXCR4
SCHEMBL11181437 0.91 RAD52 (0.52) RAD52POLBSMN1; SMN2GNAO1CXCR4
Hydrochloric Acid SCHEMBL27752774 0.91 GNAO1 (0.54) RAD52POLBSMN1; SMN2GNAO1CXCR4
SCHEMBL1623678 0.89 RAD52 (0.55) RAD52POLBSMN1; SMN2GNAO1CXCR4
SCHEMBL21367228 0.87 GNAO1 (0.47) RAD52POLBSMN1; SMN2GNAO1CXCR4
Piperazine SCHEMBL27980932 0.87 RAD52 (0.53) RAD52POLBSMN1; SMN2GNAO1CXCR4
SCHEMBL3947017 0.86 RAD52 (0.40) RAD52POLBSMN1; SMN2GNAO1CXCR4
SCHEMBL30579558 0.85 GNAO1 (0.40) RAD52POLBSMN1; SMN2GNAO1CXCR4
SCHEMBL21025824 0.83 GNAO1 (0.44) RAD52POLBSMN1; SMN2GNAO1CXCR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6355635-B1 IMIDAZOLEBENZENE, IMIDAZOLEPYRIDINE COMPOUNDS FOR TREATMENT OF OBESITY PFIZER INC. 2002-03-12 — — US claimed
US-20010039277-A1 Compounds for the treatment of obesity ELLIOTT RICHARD L (US) 2001-11-08 — — US claimed
WO-2000066578-A1 COMPOUNDS FOR THE TREATMENT OF OBESITY PFIZER PRODUCTS INC. (US) 2000-11-09 — — WO claimed
EP-4400497-A1 3CLPRO PROTEASE INHIBITOR Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. (CN) 2024-07-17 — — EP disclosed
CN-113248427-B Sulfonyl nicotinic acid derivative, amido nicotinic acid derivative, preparation method and application thereof 苏州大学 2023-05-02 — — CN disclosed
WO-2022252392-A1 SULFONAMIDO NICOTINIC ACID DERIVATIVE AND AMIDE NICOTINIC ACID DERIVATIVE, AND PREPARATION METHODS THEREFOR AND USES THEREOF 苏州大学 2022-12-08 — — WO disclosed
CN-113200908-B Tertiary amine-containing anthranilamide compound and preparation and application thereof 南华大学 2022-07-19 — — CN disclosed
CN-113248427-A Sulfonamide nicotinic acid derivative, amido nicotinic acid derivative, preparation method and application thereof 苏州大学 2021-08-13 — — CN disclosed
CN-113200908-A Tertiary amine-containing anthranilamide compound and preparation and application thereof 南华大学 2021-08-03 — — CN disclosed
US-20080275026-A1 Benzamide derivatives as oxytocin agonists and vasopressin antagonists FERRING B.V. 2008-11-06 — — US disclosed
US-7407949-B2 Benzamide derivatives as oxytocin agonists and vasopressin antagonists FERRING B.V. (NL) 2008-08-05 — — US disclosed
US-20060166971-A1 Benzamide derivatives as oxytocin agonists and vasopressin antagonists FERRING B.V. (NL) 2006-07-27 — — US disclosed
CN-1751050-A Benzamide derivatives as oxytocin agonists and vasopressin antagonists FERRING BV (NL) 2006-03-22 — — CN disclosed
EP-1592693-A1 BENZAMIDE DERIVATIVES AS OXYTOCIN AGONISTS AND VASOPRESSIN ANTAGONISTS Ferring B.V. (NL) 2005-11-09 — — EP disclosed
WO-2004072083-A1 BENZAMIDE DERIVATIVES AS OXYTOCIN AGONISTS AND VASOPRESSIN ANTAGONISTS FERRING B.V. (NL) 2004-08-26 — — WO disclosed
EP-1449844-A1 benzamide derivatives as oxytocin agonists and vasopressin antagonists FERRING B.V. (NL) 2004-08-25 — — EP disclosed
US-6514966-B2 Neuropeptide Y antagonists such as 2-chloro-5-(4-(3,4-dich loro-phenyl)-1H-imidazol-2-yl)-pyridine PFIZER INC. 2003-02-04 — — US disclosed
US-6355635-B1 IMIDAZOLEBENZENE, IMIDAZOLEPYRIDINE COMPOUNDS FOR TREATMENT OF OBESITY PFIZER INC. 2002-03-12 — — US disclosed
US-20010039277-A1 Compounds for the treatment of obesity ELLIOTT RICHARD L (US) 2001-11-08 — — US disclosed
WO-2000066578-A1 COMPOUNDS FOR THE TREATMENT OF OBESITY PFIZER PRODUCTS INC. (US) 2000-11-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080275026-A1 Benzamide derivatives as oxytocin agonists and vasopressin antagonists AVPR1A, AVPR2, AVPR1B RAD52 3582/4885POLB 3258/4885SMN1; SMN2 3618/4885
US-20060166971-A1 Benzamide derivatives as oxytocin agonists and vasopressin antagonists AVPR1A, AVPR2, AVPR1B RAD52 3582/4885POLB 3258/4885SMN1; SMN2 3618/4885
US-20010039277-A1 Compounds for the treatment of obesity NPY1R, NPY4R, NPY2R RAD52 4761/4885POLB 4226/4885SMN1; SMN2 3943/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.